CanDo

A CANcer Development mOnitor

 Coordinatore UNIVERSITAT DE VALENCIA 

 Organization address address: AVENIDA BLASCO IBANEZ 13
city: VALENCIA

contact info
Titolo: Mrs.
Nome: Angeles
Cognome: Sanchis
Email: send email
Telefono: +34 96 3983621
Fax: +34 96 3937729

 Nazionalità Coordinatore Spain [ES]
 Totale costo 5˙299˙286 €
 EC contributo 4˙000˙000 €
 Programma FP7-ICT
Specific Programme "Cooperation": Information and communication technologies
 Code Call FP7-ICT-2013-10
 Funding Scheme CP
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-01-01   -   2017-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITAT DE VALENCIA

 Organization address address: AVENIDA BLASCO IBANEZ 13
city: VALENCIA

contact info
Titolo: Mrs.
Nome: Angeles
Cognome: Sanchis
Email: send email
Telefono: +34 96 3983621
Fax: +34 96 3937729

ES (VALENCIA) coordinator 0.00
2    Bayer Pharma AG

 Organization address address: Muellerstrasse 178
city: Berlin

contact info
Titolo: Dr.
Nome: Thomas
Cognome: Krahn
Email: send email
Telefono: +49 202364125

DE (Berlin) participant 0.00
3    GILUPI GMBH

 Organization address address: AM MUEHLENBERG 11
city: POSTDAM

contact info
Titolo: Dr.
Nome: Klaus
Cognome: Luecke
Email: send email
Telefono: 4933160000000
Fax: +49 33158184780

DE (POSTDAM) participant 0.00
4    IKERLAN SCL

 Organization address address: Paseo J.M. Arizmendiarrieta 2
city: MONDRAGON

contact info
Titolo: Dr.
Nome: Chris
Cognome: Merveille
Email: send email
Telefono: +34 943712400
Fax: +34943 796 944

ES (MONDRAGON) participant 0.00
5    INTERUNIVERSITAIR MICRO-ELECTRONICACENTRUM IMEC VZW

 Organization address address: KAPELDREEF 75
city: LEUVEN

contact info
Titolo: Mrs.
Nome: Christine
Cognome: Van Houtven
Email: send email
Telefono: +32 92643446

BE (LEUVEN) participant 0.00
6    KUNGLIGA TEKNISKA HOEGSKOLAN

 Organization address address: BRINELLVAGEN 8
city: STOCKHOLM

contact info
Titolo: Mrs.
Nome: Marianne
Cognome: Fridborn
Email: send email
Telefono: +46 85537 8447

SE (STOCKHOLM) participant 0.00
7    LEIBNIZ-INSTITUT FUER PHOTONISCHE TECHNOLOGIEN E.V.

 Organization address address: Albert Einstein strasse 9
city: JENA

contact info
Titolo: Ms.
Nome: Gabriele
Cognome: Hamm
Email: send email
Telefono: +49 3641206327
Fax: +49 3641 206399

DE (JENA) participant 0.00
8    MICROFLUIDIC CHIPSHOP GMBH

 Organization address address: STOCKHOLMER STRASSE 20
city: JENA

contact info
Titolo: Dr.
Nome: Claudia
Cognome: Gärtner
Email: send email
Telefono: +49 3641 347050
Fax: +49 3641 3470590

DE (JENA) participant 0.00
9    STOCKHOLMS LAENS LANDSTING

 Organization address address: Hantverkargatan 45
city: STOCKHOLM

contact info
Nome: Erica
Cognome: Oeqvist
Email: send email
Telefono: 46858586863

SE (STOCKHOLM) participant 0.00
10    STOCKHOLMS UNIVERSITET

 Organization address address: Universitetsvaegen 10
city: STOCKHOLM

contact info
Titolo: Ms.
Nome: Ann
Cognome: Nielsen
Email: send email
Telefono: 468162594

SE (STOCKHOLM) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

ctcs    identification    blood    technologies    platform    efficacy    cando    tumor    concentrations    societal    determination    cells    cancer    anti    progression    peripheral    ctc    detection    drug   

 Obiettivo del progetto (Objective)

Through further development, integration and validation of micro-nano-bio and biophotonics systems from previous projects CanDo will develop an instrument that will permit the identification and concentration determination of rare cells in peripheral blood for two key societal challenges, early and low cost anti-cancer drug efficacy determination and cancer diagnosis/monitoring.A cellular link between the primary malignant tumor and the peripheral metastases, responsible for 90% of cancer-related deaths, has been established in the form of circulating tumor cells (CTCs) in peripheral blood. Furthermore the relatively short survival time of CTCs in peripheral blood means that their detection is indicative of tumor progression thereby providing in addition to a prognostic value an evaluation of therapeutic efficacy and early recognition of tumor progression in theranostics. In cancer patients however blood concentrations are very low (=1 CTC/1E9 cells) and current detection strategies are too insensitive, limiting use to prognosis of only those with advanced metastatic cancer. Similarly problems occur in therapeutics with anti-cancer drug development leading to lengthy and costly trials often preventing access to market. There is therefore a clear need for a novel analytical platform capable of highly reproducible and reliable identification of CTC concentrations of interest in an easily accessible format.With all relevant industrial stakeholders and users onboard CanDo is uniquely capable of delivering such a platform. Its novel cell separation/SERS analysis technologies plus nucleic acid based molecular characterization will provide an accurate CTC count with high throughput and high yield meeting both key societal challenges. Being beyond the state of art it will lead to substantial share gains not just in the high end markets of drug discovery and cancer diagnostics but due to modular technologies in others e.g. transport, security and safety and environment.

Altri progetti dello stesso programma (FP7-ICT)

DOPA (2012)

Data Supply Chains for Pools, Services and Analytics in Economics and Finance

Read More  

AUTOMICS (2012)

Pragmatic solution for parasitic-immune design of electronics ICs for automotive

Read More  

OEPI (2010)

Exploring and Monitoring Any Organisation's Environmental Performance Indicators

Read More